相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Oliver Sartor et al.
EUROPEAN UROLOGY (2023)
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
Gaetan Devos et al.
EUROPEAN UROLOGY (2023)
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Hannah L. Rush et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard et al.
LANCET (2022)
Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer
Thomas Van den Broeck et al.
MOLECULAR CANCER RESEARCH (2022)
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
Nicholas D. James et al.
JNCI CANCER SPECTRUM (2022)
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
Lisa Moris et al.
EUROPEAN UROLOGY (2020)
Making adjuvant therapy decisions with uncertain data
B. Gyawali et al.
ANNALS OF ONCOLOGY (2019)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)